Here are four things to know about the bill.
1. The bill, LD 1406, is sponsored by Maine Sen. Eloise Vitelli, D-Arrowsic.
2. It calls for greater transparency with respect to prescription drug development expenses, according to a Maine Senate news release. It is also meant to be an information source for lawmakers.
3. LD 1406, as amended, directs the Maine Health Data Organization “to collect and report on the top 25 prescription drugs that are the most frequently prescribed in the state, the most costly, and have the highest year-over-year increase in total spending,” the release states. The MDHO subsequently must establish a plan for data collection from manufacturers, and provide Maine lawmakers with an annual report on prescription drug prices. Submission of the first report is expected in April 2019.
4. Maine’s drug pricing transparency law will take affect in approximately three months after the legislative session ends.
More articles on supply chain:
McKesson adds Medtronic exec as independent director: 4 takeaways
FDA approves first drug for rare form of rickets: 3 things to know
Ascension forms global supply chain company with Australian hospital operator: 8 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.